Author:
Ballantyne Anita,Dhillon Sohita
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. World Health Organization. Breast cancer: prevention and control. 2012. http://www.who.int/cancer/detection/breastcancer/en/index1.html . Accessed 11 Mar 2013.
2. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92–8.
3. Hurvitz SA, Kakkar R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012;4(5):235–45.
4. US FDA. FDA approves new treatment for late-stage breast cancer [media release]. 22 Feb 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm .
5. Genentech Inc. Kadcyla™ (ado-trastuzumab emtansine): US prescribing information. 2013. http://www.gene.com/download/pdf/kadcyla_prescribing.pdf . Accessed 12 Mar 2013.
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献